Results 21 to 30 of about 34,931 (220)
Pediatric adrenocortical carcinoma revealed by isolated Cushing syndrome: A case report
Journal of Pediatric Surgery Case Reports, 2023 Background: Adrenocortical carcinoma accounts for less than 0.2% of all pediatric malignancies. Virilization is the most common revealing sign, whereas hyperaldosteronism and Cushing syndrome are less common.We report a case of adrenocortical carcinoma ...
Hakima Chafaaoui +4 more
doaj +1 more source
Adrenocortical Carcinoma with Hypercortisolism [PDF]
Endocrinology and Metabolism Clinics of North America, 2018 Adrenocortical carcinoma (ACC) is a rare and aggressive tumor. ACC may be associated with different syndromes of hormone excess, most frequently Cushing's syndrome with or without hypersecretion of androgens. Recent data suggest that cortisol excess is a negative prognostic factor in advanced and localized ACC.
Puglisi S +4 more
openaire +3 more sources
Giant nonfunctioning adrenal tumors: two case reports and review of the literature
Journal of Medical Case Reports, 2018 Background There are an estimated 1–2 cases per million per year of adrenocortical carcinoma in the USA. It represents a rare and aggressive malignancy; it is the second most aggressive endocrine malignant disease after anaplastic thyroid carcinoma.
George Chatzoulis +8 more
doaj +1 more source
Differential diagnosis of adrenal masses by chemical shift and dynamic gadolinium enhanced MR imaging. [PDF]
, 2003 Chemical shift MRI is widely used for identifying adenomas, but it is not a perfect method. We determined whether combined dynamic MRI methods can lead to improved diagnostic accuracy.
Akaki, Shiro +5 more
core +1 more source
Pharmaceuticals, 2022 Adrenocortical carcinoma (ACC) is a rare subtype of cancer, with a poor prognosis in children and adults. Mitotane is the only approved adrenolytic drug for the treatment of ACC, which has controversies regarding its efficacy and side effects on patients.
Alan A. Veiga +4 more
doaj +1 more source
GPER agonist G-1 decreases adrenocortical carcinoma (ACC) cell growth in vitro and in vivo [PDF]
, 2015 We have previously demonstrated that estrogen receptor (ER) alpha (ESR1) increases proliferation of adrenocortical carcinoma (ACC) through both an estrogen-dependent and -independent (induced by IGF-II/IGF1R pathways) manner.
Amendola, Donatella +16 more
core +2 more sources
MicroRNAs as potential biomarkers in adrenocortical cancer: progress and challenges
Frontiers in Endocrinology, 2016 Adrenocortical carcinoma is a rare malignancy with poor prognosis and limited therapeutic options. Over the last decade, pan-genomic analyses of genetic and epigenetic alterations and genome-wide expression profile studies allowed major advances in the ...
Nadia eCHERRADI +2 more
doaj +1 more source
Radiopharmaceuticals for Treatment of Adrenocortical Carcinoma
Pharmaceuticals, 2023 Adrenocortical carcinoma (ACC) represents a rare tumor entity with limited treatment options and usually rapid tumor progression in case of metastatic disease. As further treatment options are needed and ACC metastases are sensitive to external beam radiation, novel theranostic approaches could complement established therapeutic concepts.
Kerstin Michalski +6 more
openaire +3 more sources
Methylation status of Vitamin D receptor gene promoter in benign and malignant adrenal tumors [PDF]
, 2015 We previously showed a decreased expression of vitamin D receptor (VDR) mRNA/protein in a small group of adrenocortical carcinoma (ACC) tissues, suggesting the loss of a protective role of VDR against malignant cell growth in this cancer type ...
Cappellesso, Rocco +7 more
core +4 more sources